Form 4: Kezar Life Sciences Director Granted 5,000 Stock Options

John Franklin Fowler, a Director at Kezar Life Sciences, Inc., was granted 5,000 stock options with an exercise price of $4.46, vesting fully in one year.

Summary

• John Franklin Fowler, a Director of Kezar Life Sciences, Inc. (KZR), was granted 5,000 stock options.
• The transaction date for this grant was June 18, 2025.
• Each stock option has an exercise price of $4.46.
• The options are for the right to buy 5,000 shares of Kezar Life Sciences Common Stock.
• One hundred percent (100%) of the shares subject to the option will vest on June 18, 2026, contingent upon Mr. Fowler's continued service through that date.
• The expiration date for these stock options is June 17, 2035.
• Following this transaction, Mr. Fowler beneficially owns 5,000 derivative securities (stock options).

Sentiment

Score: 7

Explanation: The grant of stock options to a director is generally viewed positively as it aligns the director's interests with shareholders and is a standard compensation practice, indicating stability in governance.

Positives

• The grant of stock options to a director aligns their financial interests with those of the shareholders, encouraging long-term commitment and performance.
• The vesting schedule, contingent on continued service, promotes retention of key board members.

Future Outlook

The stock options are scheduled to vest fully on June 18, 2026, contingent on the director's continued service, indicating a future milestone for the equity compensation.

Industry Context

The grant of stock options to directors is a common practice in the biotechnology and life sciences industry, serving as a key component of executive and board compensation packages to incentivize long-term value creation and align interests with shareholders.

Comparison to Industry Standards

• The grant of stock options to a director is a standard compensation practice across publicly traded companies, particularly within the biotechnology sector, to attract and retain qualified board members.
• The vesting schedule of 100% after one year is a common structure for director equity grants, aiming to provide immediate alignment while ensuring continued service.

Related Party Transactions

• John Franklin Fowler, a Director of Kezar Life Sciences, Inc., received a grant of 5,000 stock options as part of his compensation, which constitutes a transaction with a related party (an insider).

Stakeholder Impact

• Shareholders: The grant aligns the director's financial incentives with shareholder value creation, potentially leading to better long-term performance.
• Employees: While not directly impacted, such grants are part of a broader compensation philosophy that can influence overall company culture and talent retention strategies.

Next Steps

• The stock options are scheduled to vest on June 18, 2026, subject to the director's continued service.

Key Dates

Keywords

Kezar Life Sciences, KZR, Stock Option, Director Compensation, Insider Transaction, SEC Form 4, Equity Grant, Biotechnology